We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM-Associated Fanconi Anemia The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using ...

Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...

Please provide your email address to receive an email when new articles are posted on . Patients with small cell lung cancer who had higher levels of detectable ctDNA mutations at diagnosis had worse ...

Researchers working on blood-based cancer screening have reached a threshold that could change how early-stage tumors are ...

After surgery for colon cancer, many patients face the question of whether follow-up chemotherapy is necessary to prevent a possible relapse. The decision is particularly difficult in so-called Stage ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...

Circulating tumor cells were first described in 1869 by Thomas Ashworth, an Australian pathologist who observed them in a peripheral blood sample taken from a patient with metastatic cancer. 1 They ...

Glioblastoma (GBM) is an aggressive brain tumor characterized by marked intra- and inter-tumoral heterogeneity and inevitable recurrence. Although extracranial metastasis is rare, circulating tumor ...